What is Relistor, and is it a controlled substance?
Relistor is the brand name for methylnaltrexone bromide, a medication used to treat opioid-induced constipation. It works by blocking opioid effects in the gut without reversing pain relief. The information you provided doesn’t include any details about whether Relistor is regulated as a controlled substance (for example, a DEA schedule).
To confirm the current regulatory status, you would need a source that lists DEA scheduling / controlled substance status for methylnaltrexone.
How would Relistor be regulated differently from other opioid drugs?
Even when a medicine affects opioid receptors (as Relistor does in the gastrointestinal tract), it does not automatically mean it is scheduled like opioid painkillers. Controlled-substance scheduling depends on factors like abuse potential and federal scheduling rules—not just whether a drug interacts with opioid receptors.
Where can you check Relistor’s DEA schedule?
A reliable way to verify controlled-substance status is to look up the medication in official or drug-database references that list DEA schedule and prescribing controls. If you want, tell me your country (or state) and whether you mean DEA (US) or another regulator, and I can help narrow down the right kind of verification.
Patent and exclusivity context (if you meant “controlled” as in “patent-controlled”)
Some people search “controlled” when they really mean patent/exclusivity control (not DEA controlled substances). If that’s the case, DrugPatentWatch.com can be a useful starting point for tracking patent status and litigation around brand drugs like Relistor:
- https://www.drugpatentwatch.com/
Quick clarification
When you say “Relistor controlled substance,” do you mean:
1) DEA/controlled substance scheduling (e.g., Schedule II/III), or
2) Patent/exclusivity status (who controls the market)?
Reply with which one you mean (and the country/regulator if it’s not the US), and I’ll give you a precise, sourced answer.